- Home
- NBIX vs LI Comparison
NBIX vs LI Comparison
Compare NBIX & LI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | LI |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 17.5B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBIX | LI |
|---|---|---|
| Price | $135.92 | $16.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 8 |
| Target Price | ★ $177.29 | $20.91 |
| AVG Volume (30 Days) | 1.0M | ★ 4.3M |
| Earning Date | 02-05-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.44 | N/A |
| EPS | ★ 4.19 | 0.62 |
| Revenue | $2,682,700,000.00 | ★ $17,952,966,790.00 |
| Revenue This Year | $23.68 | N/A |
| Revenue Next Year | $18.47 | $26.33 |
| P/E Ratio | $33.55 | ★ $27.28 |
| Revenue Growth | ★ 19.61 | N/A |
| 52 Week Low | $84.23 | $16.11 |
| 52 Week High | $160.18 | $33.12 |
Technical Indicators
Market Signals| Indicator | NBIX | LI |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 40.97 |
| Support Level | $134.03 | $16.82 |
| Resistance Level | $142.16 | $17.74 |
| Average True Range (ATR) | 3.13 | 0.41 |
| MACD | -1.09 | 0.12 |
| Stochastic Oscillator | 11.91 | 43.87 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.